The Value of Extent of Resection of Glioblastomas: Clinical Evidence and Current Approach

Current Neurology and Neuroscience Reports

Volumn 15, Issue 2, 2015, Pages

  Almeida, Joao Paulo ^a   Chaichana, Kaisorn L ^a   Rincon Torroella, Jordina ^a   Quinones Hinojosa, Alfredo ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Glioblastomas; Intraoperative magnetic resonance imaging; Intraoperative mapping; Prognosis; Resection; Surgery; Ultrasound

Indexed keywords

AGE; BRAIN MAPPING; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; EXTENT OF RESECTION; GLIOBLASTOMA; HUMAN; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; NERVOUS SYSTEM FUNCTION; NEURONAVIGATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SURGICAL TECHNIQUE; SURGICAL TECHNOLOGY; ULTRASOUND SURGERY; BRAIN NEOPLASMS; EVIDENCE BASED MEDICINE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

BRAIN NEOPLASMS; EVIDENCE-BASED MEDICINE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEURONAVIGATION; NEUROSURGICAL PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

EID: 84924862661     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0517-x     Document Type: Review

References (107)

1. Ostrom QT et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15 Suppl 2:ii1–56.
2. Lacroix M et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8.
3. Chaichana KL et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45.
4. Chaichana KL et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113–22. Retrospective study evaluating the impact of EOR according to volumetric analyzes on the survival of GBM patients This study observed that extent of resection and residual tumor volume were significantly associated with survival, where the thresholds are 70% and 5 cm3, respectively.
5. Sanai N et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. Clinical study based on volumetric analyzes of EOR of glioblastoma. The authors demonstrate a stepwise improvement in survival associated with higher EOR rates. Significant survival advantage was associated with subtotal resection as low as 78 %.
6. Stummer W et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401.
7. Chaichana K et al. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg. 2010;112(5):997–1004.
8. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114–23.
9. Leibetseder A et al. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol. 2013;15(1):112–21.
10. Juratli TA et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110(3):325–33.
11. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6(3):227–35.
12. Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
13. Chaichana KL et al. When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg. 2014;82(1–2):e257–65.
14. Chaichana KL et al. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J Clin Neurosci. 2013;20(10):1422–6.
15. Laws ER et al. Surgical management of intracranial gliomas—does radical resection improve outcome? Acta Neurochir Suppl. 2003;85:47–53.
16. McGirt MJ et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.
17. Pichlmeier U et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol. 2008;10(6):1025–34.
18. Sanai N, Berger MS. Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris). 2011;167(10):648–54.
19. Ushio Y et al. Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo). 2005;45(9):454–60. discussion 460–1.
20. McGirt MJ et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463–9. discussion 469–70.
21. Vecht CJ et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry. 1990;53(6):466–71.
22. Shibamoto Y et al. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother Oncol. 1990;18(1):9–17.
23. Simpson JR et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26(2):239–44.
24. Dinapoli RP et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol. 1993;11(7):1316–21.
25. Jeremic B et al. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21(2):177–85.
26. Huber A et al. Supratentorial glioma: analysis of clinical and temporal parameters in 163 cases. Neurochirurgia (Stuttg). 1993;36(6):189–93.
27. Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer. 1995;75(11):2727–31.
28. Barker 2nd FG et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg. 1996;84(3):442–8.
29. Buckner JC et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001;92(2):420–33.
30. Brown PD et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76(3):283–91.
31. Stark AM et al. Glioblastoma multiforme—report of 267 cases treated at a single institution. Surg Neurol. 2005;63(2):162–9. discussion 169.
32. McGirt MJ, Gokaslan ZL, Chaichana KL. Preoperative grading scale to predict survival in patients undergoing resection of malignant primary osseous spinal neoplasms. Spine J. 2011;11(3):190–6.
33. Oszvald A et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012;116(2):357–64.
34. Hollerhage HG et al. Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme. Acta Neurochir (Wien). 1991;113(1–2):31–7.
35. Phillips TL et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys. 1991;21(3):709–14.
36. Duncan GG et al. The treatment of adult supratentorial high grade astrocytomas. J Neurooncol. 1992;13(1):63–72.
37. Kowalczuk A et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997;41(5):1028–36. discussion 1036–8.
38. Sandberg-Wollheim M et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer. 1991;68(1):22–9.
39. Orringer D et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851–9. Retrospective study evaluating the impact of EOR according to volumetric analyzes on the survival of GBM patients. Significant survival advantage associated with an EOR of 90 % or more. It also shows the limitations of the surgeon’s intraoperative assessment of the EOR when compared to postop MRI scan.
40. Grabowski MM et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115–23. Retrospective study evaluating the impact of EOR according to volumetric analyzes on the survival of GBM patients. This study suggests that residual tumor volume is the most significant radiological predictor of survival in glioblastoma patients.
41. Gonzalez-Darder JM et al. Multimodal navigation in the functional microsurgical resection of intrinsic brain tumors located in eloquent motor areas: role of tractography. Neurosurg Focus. 2010;28(2):E5.
42. Berntsen EM et al. Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery. 2010;67(2):251–64.
43. Yu CS et al. Diffusion tensor tractography in patients with cerebral tumors: a helpful technique for neurosurgical planning and postoperative assessment. Eur J Radiol. 2005;56(2):197–204.
44. Romano A et al. Role of magnetic resonance tractography in the preoperative planning and intraoperative assessment of patients with intra-axial brain tumours. Radiol Med. 2007;112(6):906–20.
45. Kumar A et al. The role of neuronavigation-guided functional MRI and diffusion tensor tractography along with cortical stimulation in patients with eloquent cortex lesions. Br J Neurosurg. 2014;28(2):226–33.
46. Mandelli ML et al. Quantifying accuracy and precision of diffusion MR tractography of the corticospinal tract in brain tumors. J Neurosurg. 2014;121(2):349–58.
47. Wu JS et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007;61(5):935–48. discussion 948–9.
48. Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev. 2014;1, CD009685.
49. Berman JI et al. Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging. J Neurosurg. 2007;107(3):488–94.
50. Berman JI et al. Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. J Neurosurg. 2004;101(1):66–72.
51. Makuuchi M, Torzilli G, Machi J. History of intraoperative ultrasound. Ultrasound Med Biol. 1998;24(9):1229–42.
52. Le Roux PD et al. Low grade gliomas: comparison of intraoperative ultrasound characteristics with preoperative imaging studies. J Neurooncol. 1992;13(2):189–98.
53. Dohrmann GJ, Rubin JM. History of intraoperative ultrasound in neurosurgery. Neurosurg Clin N Am. 2001;12(1):155–66. ix.
54. Moiyadi AV et al. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien). 2013;155(12):2217–25. Large clinical series demonstrating the impact of ultrasound-guided surgery. In this study the use of the intraoperative imaging prompted further resection in 59 % cases. In the malignant gliomas (51 cases), gross-total resection was achieved in 47 % cases, increasing to 88 % in the “resectable” subgroup.
55. Moiyadi A, Shetty P. Objective assessment of utility of intraoperative ultrasound in resection of central nervous system tumors: a cost-effective tool for intraoperative navigation in neurosurgery. J Neurosci Rural Pract. 2011;2(1):4–11.
56. Unsgaard G et al. Brain operations guided by real-time two-dimensional ultrasound: new possibilities as a result of improved image quality. Neurosurgery. 2002;51(2):402–11. discussion 411–2.
57. Unsgaard G et al. Neuronavigation by intraoperative three-dimensional ultrasound: initial experience during brain tumor resection. Neurosurgery. 2002;50(4):804–12. discussion 812.
58. Padayachy LC, Fieggen G. Intraoperative ultrasound-guidance in neurosurgery. World Neurosurg. 2013;82(3–4):e409–11.
59. Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol. 2014;16(4):284.
60. Unsgaard G et al. Intra-operative 3D ultrasound in neurosurgery. Acta Neurochir (Wien). 2006;148(3):235–53. discussion 253.
61. Solheim O et al. Ultrasound-guided operations in unselected high-grade gliomas—overall results, impact of image quality and patient selection. Acta Neurochir (Wien). 2010;152(11):1873–86.
62. Saether CA et al. Did survival improve after the implementation of intraoperative neuronavigation and 3D ultrasound in glioblastoma surgery? A retrospective analysis of 192 primary operations. J Neurol Surg A Cent Eur Neurosurg. 2012;73(2):73–8.
63. Black PM et al. Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications. Neurosurgery. 1997;41(4):831–42. discussion 842–5.
64. Kubben PL et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062–70.
65. Knauth M et al. Intraoperative MR imaging increases the extent of tumor resection in patients with high-grade gliomas. AJNR Am J Neuroradiol. 1999;20(9):1642–6.
66. Wirtz CR et al. Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery. 2000;46(5):1112–20. discussion 1120–2.
67. Bohinski RJ et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery. 2001;49(5):1133–43. discussion 1143–4.
68. Nimsky C et al. Glioma surgery evaluated by intraoperative low-field magnetic resonance imaging. Acta Neurochir Suppl. 2003;85:55–63.
69. Hirschberg H et al. Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg. 2005;48(2):77–84.
70. Schneider JP et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme—a quantitative radiological analysis. Neuroradiology. 2005;47(7):489–500.
71. Muragaki Y et al. Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl. 2006;98:67–75.
72. Busse H et al. Advanced approach for intraoperative MRI guidance and potential benefit for neurosurgical applications. J Magn Reson Imaging. 2006;24(1):140–51.
73. Nimsky C et al. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res. 2006;28(5):482–7.
74. Hatiboglu MA et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery. 2009;64(6):1073–81. discussion 1081.
75. Lenaburg HJ, Inkabi KE, Vitaz TW. The use of intraoperative MRI for the treatment of glioblastoma multiforme. Technol Cancer Res Treat. 2009;8(2):159–62.
76. Senft C et al. Low field intraoperative MRI-guided surgery of gliomas: a single center experience. Clin Neurol Neurosurg. 2010;112(3):237–43.
77. Senft C et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997–1003. Randomized controlled trial demonstrating the benefits of intraoperative MRI to achieve large resections of glioblastomas. The authors show that more patients in the intraoperative MRI group had complete tumor resection (23 [96 %] of 24 patients) than did in the control group (17 [68 %] of 25, p = 0 · 023).
78. Foroglou N, Zamani A, Black P. Intra-operative MRI (iop-MR) for brain tumour surgery. Br J Neurosurg. 2009;23(1):14–22.
79. Alexander 3rd E et al. The present and future role of intraoperative MRI in neurosurgical procedures. Stereotact Funct Neurosurg. 1997;68(4 Pt 1):10–7.
80. Gerlach R et al. Feasibility of Polestar N20, an ultra-low-field intraoperative magnetic resonance imaging system in resection control of pituitary macroadenomas: lessons learned from the first 40 cases. Neurosurgery. 2008;63(2):272–84. discussion 284–5.
81. D’Amico RS, Kennedy BC, Bruce JN. Neurosurgical oncology: advances in operative technologies and adjuncts. J Neurooncol. 2014;119(3):451–63.
82. Albert FK et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34(1):45–60. discussion 60–1.
83. Zhao S et al. Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS ONE. 2013;8(5):e63682.
84. Regula J et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX—a pilot study. Gut. 1995;36(1):67–75.
85. Kennedy AS. Radiation oncology approaches in liver malignancies. Am Soc Clin Oncol Educ Book. 2014;e150-e155. doi: 10.14694/EdBook_AM.2014.34.e150.
86. el-Sharabasy MM et al. Porphyrin metabolism in some malignant diseases. Br J Cancer. 1992;65(3):409–12.
87. Pottier RH et al. Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo. Photochem Photobiol. 1986;44(5):679–87.
88. Roberts DW et al. Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am. 2012;23(3):371–7.
89. Stummer W et al. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien). 1998;140(10):995–1000.
90. Duffner F et al. Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neurooncol. 2005;71(2):107–11.
91. Stummer W et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93(6):1003–13.
92. Lilge L et al. The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. Br J Cancer. 1996;73(3):332–43.
93. Diez Valle R et al. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2011;102(1):105–13.
94. Schucht P et al. 5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma. Acta Neurochir (Wien). 2014;156(2):305–12. discussion 312.
95. Stummer W et al. 5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery. 2014;74(3):310–9. discussion 319–20.
96. Li Y et al. Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies. World Neurosurg. 2014;82(1–2):175–85.
97. Miyatake S et al. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report. Neurosurgery. 2007;61(5):E1101–3. discussion E1103-4.
98. Rasmussen T, Penfield W. Further studies of the sensory and motor cerebral cortex of man. Fed Proc. 1947;6(2):452–60.
99. Schucht P et al. Subcortical electrostimulation to identify network subserving motor control. Hum Brain Mapp. 2013;34(11):3023–30.
100. Duffau H. Acute functional reorganisation of the human motor cortex during resection of central lesions: a study using intraoperative brain mapping. J Neurol Neurosurg Psychiatry. 2001;70(4):506–13.
101. Fontaine D, Capelle L, Duffau H. Somatotopy of the supplementary motor area: evidence from correlation of the extent of surgical resection with the clinical patterns of deficit. Neurosurgery. 2002;50(2):297–303. discussion 303–5.
102. Ranck Jr JB. Which elements are excited in electrical stimulation of mammalian central nervous system: a review. Brain Res. 1975;98(3):417–40.
103. Sanai N, Berger MS. Intraoperative stimulation techniques for functional pathway preservation and glioma resection. Neurosurg Focus. 2010;28(2):E1.
104. Duffau H. A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. Neurochirurgie. 2013;59(1):2–8.
105. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med. 2008;358(1):18–27.
106. Sanai N, Berger MS. Mapping the horizon: techniques to optimize tumor resection before and during surgery. Clin Neurosurg. 2008;55:14–9.
107. De Witt Hamer PC et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559–65.